Scientific article
English

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Published inAntiviral Research, vol. 150, p. 9-14
Publication date2018
Abstract

Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.

Citation (ISO format)
LEBLEBICIOGLU, Hakan et al. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. In: Antiviral Research, 2018, vol. 150, p. 9–14. doi: 10.1016/j.antiviral.2017.12.001
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0166-3542
441views
0downloads

Technical informations

Creation12/06/2018 15:34:00
First validation12/06/2018 15:34:00
Update15/03/2023 08:26:57
Status update15/03/2023 08:26:56
Last indexation31/10/2024 10:44:07
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack